版本:
中国

BRIEF-Novartis' Cart-T Therapy CTl019 gets FDA breakthrough therapy designation

April 18 Novartis Ag

* Novartis car-t cell therapy ctl019 receives FDA breakthrough therapy designation for treatment of adult patients with r/r DLBCL

* Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

* R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation Source text for Eikon: Further company coverage: (Reporting by John Revill)

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐